Page 71 - Read Online

Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50 Page 161

297. Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nat Rev Drug Discov 2017;16:387-99. DOI
PubMed
298. Planul A, Dalkara D. Vectors and gene delivery to the retina. Annu Rev Vis Sci 2017;3:121-40. DOI
299. Hill AB, Chen M, Chen CK, Pfeifer BA, Jones CH. Overcoming gene-delivery hurdles: physiological considerations for nonviral
vectors. Trends Biotechnol 2016;34:91-105. DOI PubMed PMC
300. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther 2012;20:1298-304. DOI
PubMed PMC
301. Butt MH, Zaman M, Ahmad A, et al. Appraisal for the potential of viral and nonviral vectors in gene therapy: a review. Genes
2022;13:1370. DOI PubMed PMC
302. Dey D, Evans GR. Suicide gene therapy by herpes simplex virus-1 thymidine kinase (HSV-TK). Targets Gene Ther 2011:65. DOI
303. Harrison GS, Glode LM. Current challenges of gene therapy for prostate cancer. Oncology 1997;11:845-55. PubMed
304. Han C, Deng Y, Xu W, et al. The roles of tumor-associated macrophages in prostate cancer. J Oncol 2022;2022:8580043. DOI
PubMed PMC
305. Msaouel P, Iankov ID, Allen C, et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate
2009;69:82-91. DOI PubMed PMC
306. Li J, Røise JJ, He M, Das R, Murthy N. Non-viral strategies for delivering genome editing enzymes. Adv Drug Deliv Rev
2021;168:99-117. DOI PubMed
307. Gregg JR, Thompson TC. Considering the potential for gene-based therapy in prostate cancer. Nat Rev Urol 2021;18:170-84. DOI
PubMed
308. van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
for treatment of prostate cancer: first results and review of the literature. Prostate Cancer Prostatic Dis 1999;2:227-33. DOI PubMed
309. Darvish L, Bahreyni-Toossi MT, Aghaee-Bakhtiari SH, et al. Inducing apoptosis by using microRNA in radio-resistant prostate
cancer: an in-silico study with an in-vitro validation. Mol Biol Rep 2023;50:6063-74. DOI
310. Teh BS, Ishiyama H, Mai WY, Thompson TC, Butler EB. Long-term outcome of a phase II trial using immunomodulatory in situ
gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate
cancer. Int J Radiat Oncol 2015;4:377-86. DOI
311. Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, current, and future of immunotherapies for prostate
cancer. Front Oncol 2019;9:884. DOI PubMed PMC
312. LeVee A, Lin CY, Posadas E, et al. Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a
review of current evidence and patient selection. Onco Targets Ther 2021;14:4819-32. DOI PubMed PMC
313. Powers E, Karachaliou GS, Kao C, et al. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol
Oncol 2020;13:144. DOI PubMed PMC
314. Gdor Y, Timme TL, Kadmon D, Miles BJ, Thompson TC. Strategies for prostate cancer gene therapy. Am J Cancer 2004;3:79-95.
DOI
315. Lin Y, Wagner E, Lächelt U. Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP. Biomater Sci
2022;10:1166-92. DOI PubMed
316. Kanvinde S, Kulkarni T, Deodhar S, Bhattacharya D, Dasgupta A. Non-viral vectors for delivery of nucleic acid therapies for cancer.
BioTech 2022;11:6. DOI PubMed PMC
317. McCrudden CM, McBride JW, McCaffrey J, et al. Gene therapy with RALA/iNOS composite nanoparticles significantly enhances
survival in a model of metastatic prostate cancer. Cancer Nanotechnol 2018;9:5. DOI PubMed PMC
318. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the
treatment of prostate cancer. Prostate 2009;69:1128-41. DOI PubMed PMC
319. Son HA, Zhang L, Cuong BK, et al. Combination of vaccine-strain measles and mumps viruses enhances oncolytic activity against
human solid malignancies. Cancer Invest 2018;36:106-17. DOI
320. Durso RJ, Andjelic S, Gardner JP, et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent
cellular and humoral immune responses. Clin Cancer Res 2007;13:3999-4008. DOI
321. Mansfield DC, Kyula JN, Rosenfelder N, et al. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene
therapy in prostate cancer. Gene Ther 2016;23:357-68. DOI PubMed PMC
322. Slovin SF, Kehoe M, Durso R, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific
membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013;31:943-9. DOI
323. Vajda A, Marignol L, Foley R, Lynch TH, Lawler M, Hollywood D. Clinical potential of gene-directed enzyme prodrug therapy to
improve radiation therapy in prostate cancer patients. Cancer Treat Rev 2011;37:643-54. DOI PubMed